Blood test may take the guesswork out of transplant drug dosing

NCT ID NCT07718633

Not yet recruiting Disease control Sponsor: Natera, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether a blood test called Prospera can help doctors better adjust anti-rejection medications in people who have recently received a kidney transplant. The test measures DNA from the donor kidney to spot early signs of rejection or over-suppression. Researchers will compare outcomes like graft survival, kidney function, and side effects between patients managed with the test and those receiving standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a blood test called Prospera that measures donor-derived cell-free DNA to guide immunosuppressant dosing
What this could lead to: If successful, this blood test could help doctors personalize anti-rejection medication for kidney transplant recipients, potentially reducing organ rejection and drug side effects.
What could go wrong: The test may not improve outcomes over standard care, and false positives or negatives could lead to unnecessary or missed medication changes. As a diagnostic tool, it does not directly treat the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOSUPPRESION KIDNEY TRANSPLANT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.